The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial†
Open accessAbstract
Ursodeoxycholic acid (UDCA) is a safe medical therapy for primary biliary cirrhosis (PBC), but its effect on liver histology remains uncertain. Budesonide is a glucocorticoid with high receptor activity and high first-pass metabolism in liver. We evaluated the combination of budesonide and UDCA on liver histology and compared this with UDCA alone in a 3-year prospective, randomized, open multicenter study. Patients with PBC (n = 77), at stages I to III, were randomized into 2 treatment arms, A (n = 41): budesonide 6 mg/d and UDCA 15 mg/kg/d and B (n = 36): UDCA 15 mg/kg/d. Liver histology was assessed at the beginning and at the end of the study. Liver function tests and glucose and cortisol values were determined every 4 months. Paired liver biopsy specimens were available from 69 patients (A = 37 and B = 32). Stage improved 22% in group A but deteriorated 20% in group B (P = .009). Fibrosis decreased 25% in group A but increased 70% in group B (P = .0009). S-PIIINP decreased significantly in group A. Inflammation decreased in both groups, 34% in group A (P = .02), but only 10% in group B (P = NS). Serum liver enzymes decreased significantly in both treatment arms. Bilirubin values rose in group B but stayed stable in group A (A/B P = .002). A mild systemic glucocorticoid effect from budesonide was evident after 2 years. In conclusion, budesonide combined with UDCA improved liver histology, whereas the effect of UDCA alone was mainly on laboratory values. Studies with longer follow-up using a combination of budesonide and UDCA are warranted to confirm safety and effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, in a subsequent 3-year randomised non-blinded study performed in non-cirrhotic PBC patients (n=77), budesonide 6 mg/day plus UDCA (n=46) was associated with a 25% regression in liver fibrosis.160”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [160]
In the citing paper
“However, despite encouraging results, note must be taken of a high rate of fibrosis progression (an increase of 70%) in patients receiving UDCA monotherapy.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [160]
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bédossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,107
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A. B. R., Williams, C., Nilsson, L., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 564
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 459
Corpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315
COMBES, B., Carithers, R. L., Maddrey, W. C., Lin, D., McDonald, M. F., Wheeler, D. E., Eigenbrodt, E. H., Muñoz, S. J., Rubin, R., Garcia-Tsao, G., et al. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 303
Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.
Ryrfeldt, Å., Andersson, P., Edsbäcker, S., Tönnesson, M., Davies, D., & Pauwels, R. (1982) · PubMed · Cited by 301
Cited by
Sorted by citations
Items 201–222 of 222
A case of primary biliary cirrhosis: First report from Bangladesh
Mamun-Al-Mahtab, M.-A.-M., Uddin, K., Rahman, S., Khan, M., Kamal, Bhuiyan, M., & Hussain, G. (2010) · Clinical and Experimental Medical Journal · doi:10.1556/cemed.4.2010.1.18
Zollner, G., & Trauner, M. A. (2014) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-014-0061-2
Autoimmune liver diseases: internist’s guide from bench to bedside
Visconti, M. (2015) · Italian Journal of Medicine · doi:10.4081/itjm.2015.508
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Corpechot, C. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.870031
Immunosuppressive therapy for primary biliary cirrhosis: Do we need in future?
Zeniya, M., & Wada, T. (2014) · Hepatology Research · doi:10.1111/hepr.12245
La cirrhose biliaire primitive : actualités
Corpechot, C. (2013)
Clinical aspects of primary biliary cirrhosis
Beuers, U. H., & Bastiaansen, B. A. J. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9353-1_17
Features, prognosis and management of primary biliary cirrhosis in the era of ursodeoxycholic acid
Poupon, R. Y., Chazouillères, O., Chrétien, Y., & Corpechot, C. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9644-0_37
Targets and investigative treatments for primary biliary cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1227240
ABC Transporters Involved in Cholestasis
Cuperus, F. J. C., Gautherot, J., Halilbasic, E., Claudel, T., & Trauner, M. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679430.ch6
Carey, E. J., & Levy, C. (2018) · Clinics in Liver Disease · doi:10.1016/s1089-3261(18)30044-8
Fontanella, A., Nardi, R., Masina, M., & Uomo, G. (2017) · Italian Journal of Medicine · doi:10.4081/itjm.q.2017.7
Advances in treatment options for patients with primary biliary cholangitis
Parés, A. R. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1394840
Transition from Conventional Drugs to Promising Drugs for Primary Biliary Cholangitis
Dohmen, K. (2017) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2017.04.555634
Bassendine, M. F. (2011) · Wiley eBooks · doi:10.1002/9781444341294.ch15
Wang, Z., Jin, R., Hao, M., Xie, Y., Wang, H., & Feng, B. (2021) · Research Square · doi:10.21203/rs.3.rs-152187/v1
Treatment of primary biliary cirrhosis: current standards
Poupon, R. Y., Corpechot, C., Carrat, F., Chrétien, Y., & Poupon, R. E. (2007) · Springer eBooks · doi:10.1007/1-4020-2916-0_17
Yao, T.-T., Qian, J., & Wang, G. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.03.007
Entzündliche Gallenwegserkrankungen
Höblinger, A., Jonas, S., Gäbelein, G., & Sauerbruch, T. (2015) · Springer eBooks · doi:10.1007/978-3-642-14301-4_24
Poupon, R. Y. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6252-0_22
Research Progress in the Treatment of Primary Biliary Cholangitis with Chinese and Western Medicine
陈, 坤. (2024) · Traditional Chinese Medicine · doi:10.12677/tcm.2024.132041
Metadata
- Authors
- Rautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., Pikkarainen, P., Nuutinen, H., & Färkkilä, M.
- Affiliations
- Helsinki University Hospital (FI)
- Tampere University Hospital (FI)
- Turku University Hospital (FI)
- Corresponding author
- Rautiainen, Henna
- ORCID
- Färkkilä, Martti
- Venue
- Hepatology
- Published
- 2005-04
- Volume
- 41
- Issue
- 4
- Pages
- 747-752
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2089585697
- Cited by
- 222
- References
- 23
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 6 · 2023: 4 · 2022: 9 · 2021: 6 · 2020: 15 · 2019: 9 · 2018: 11 · 2017: 13 · 2016: 13 · 2015: 18 · 2014: 19 · 2013: 9 · 2012: 11
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mary and Georg C Ehrnrooth Foundation
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- primary biliary cirrhosis, budesonide, ursodeoxycholic acid, combination therapy, liver histopathology, liver fibrosis, liver inflammation, glucocorticoid adverse effects, serum bilirubin, liver function tests
- MeSH terms
- Adult, Aged, Drug Therapy, Combination, Glucocorticoids, Humans, Liver, Liver Cirrhosis, Liver Cirrhosis, Biliary, Middle Aged, Prospective Studies, Ursodeoxycholic Acid, Budesonide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
